Factors affecting the effectiveness/productivity of therapeutic plasma exchange in the treatment of immune-mediated neurologic disorders – a pilot study

Marija Vraneš; Aleksandar Lazović; Bela Balint; Vladimir Jakovljević; Milena Todorović Balint; Tatjana Bošković Matić

doi:10.2298/VSP241022030V

Marija Vraneš University Clinical Center Kragujevac, Blood Bank Department, Kragujevac, Serbia
Aleksandar Lazović University Clinical Center Kragujevac, Department of Surgery, Kragujevac, Serbi
Bela Balint ‡Serbian Academy of Sciences and Arts, Department of Medical Sciences; §University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
Vladimir Jakovljević University of Kragujevac, Faculty of Medical Sciences, Department of Physiology, Center of Excellence for Redox Balance Research in Cardiovascular and Metabolic Disorders, Kragujevac, Serbia; University IM Sechenov, 1st Moscow State Medical, Department of Human Pathology, Moscow, Russia
Milena Todorović Balint University Clinical Center of Serbia, Clinic for Hematology, Belgrade, Serbia; University of Belgrade, Faculty of Medicine, Belgrade, Serbia
Tatjana Bošković Matić University of Kragujevac, Faculty of Medical Sciences, Department of Neurology Kragujevac, Serbia

DOI: https://doi.org/10.2298/VSP241022030V

Keywords: blood component removal;, guillain-barre syndrome;, myasthenia gravis;, multiple sclerosis;, treatment outcome

Abstract

Background/Aim. Standard treatment for immune-mediated neurologic disorders (IMNDs) involves the use of immunosuppressive drugs and other therapies. Therapeutic plasma exchange (TPE) is an effective supplementary immunomodulatory approach. Its main goal is to decrease patients’ load of pathogenic factors (including autoantibodies) to the levels that will allow clinical improvement. Immunosuppressive medications used simultaneously with TPE reduce the “rebound rise” of autoantibody synthesis. The aim of the study was to evaluate the effectiveness of our own standardized TPE protocol and determine the correlation of TPE treatment outcomes with paraclinical (laboratory) and apheresis parameters/data. Methods. The study included 32 patients with myasthenia gravis, Guillain-Barré syndrome or acute polyradiculoneuropathy, and multiple sclerosis. TPEs were carried out using Spectra-Optia^® (Terumo-BCT, USA). Properties of our apheresis protocol used for IMND patients were as follows: a) total treatment – five single TPE procedures; b) TPE frequency – every other day; c) removed plasma – one patient’s circulating plasma volume (range 2,800–3,100 mL). TPE effectiveness was determined based on recovery of neurologic deficiency and peripheral nerve conduction, positive findings in some paraclinical (laboratory) tests, and apheresis data monitoring. Results. Using the described apheresis protocol, a clear positive therapeutic effect was observed in patients treated by TPE procedures with no interruption. TPEs were advantageous in 84.4% of patients (effectiveness rate 89.3%; non-response rate 10.7%), while in 15.6% of cases, treatment was not completed due to patients’ severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (followed by coronavirus disease 19 – COVID-19). Patients who completed five single TPEs had evident clinical improvement in terms of disability scale, muscle weakness, or neural conduction deficit. In the follow-up period, no relapses were observed. Significantly reduced values of erythrocyte parameters (especially hematocrit levels) were correlated with higher TPE effectiveness, due to increased plasma/blood cell volume ratio, followed by higher plasma-collection/removal efficacy. Other examined laboratory findings did not show a positive correlation with TPE effectiveness/productivity. Severe adverse events did not occur. There were no relapses in the following 6 months. Conclusion. In this study, the reduced levels of erythrocyte parameters (particularly hematocrit levels) were associated with an increased TPE effectiveness. For definitive conclusions, further randomized and larger clinical investigations are needed

References

Balint B, Bogdanović G, Dimitrijević G. Hemapheresis. In: Balint B, editor. Transfusiology. Beograd: Zavod za udžbenike i nas-tavna sredstva; 2004. p. 455–77. (Serbian)

Valbonesi M, Garelli S, Montani F, Manca F, Cantarella S. Plas-ma exchange and immune complex diseases: the predictability of immune complexes removal to clinical response. Vox Sang 1982; 42(1): 27–32.

Garraud O. Therapeutic plasma exchange, 2019 and beyond. Transfus Apher Sci 2019; 58(3): 226–7.

Fernández-Zarzoso M, Gómez-Seguí I, de la Rubia J. Therapeutic plasma exchange: Review of current indications. Transfus Apher Sci 2019; 58(3): 247–53.

Jacob S, Mazibrada G, Irani SR, Jacob A, Yudina A. The role of plasma exchange in the treatment of refractory autoimmune neurological diseases: A narrative review. J Neuroimmune Pharmacol 2021; 16(4): 806–17.

Sanchez AP, Balogun RA. Therapeutic plasma exchange in the critically ill patient: Technology and indications. Adv Chronic Kidney Dis 2021; 28(1): 59–73.

Dogra A, Rana K, Rathod C, Prakash S. Outcome of therapeutic plasma exchange in Myasthenia gravis patients. J Family Med Prim Care 2020; 9(12): 5971–5.

Boada M, Martínez-Lage P, Serrano-Castro P, Costa M, Páez A. Therapeutic plasma exchange with albumin: a new approach to treat Alzheimer’s disease. Expert Rev Neurother 2021; 21(8): 843–9.

Chevret S, Hughes RA, Annane D. Plasma exchange for Guil-lain-Barré syndrome. Cochrane Database Syst Rev 2017; 2(2): CD001798.

Connelly-Smith L, Alquist CR, Aqui NA, Hofmann JC, Klingel R, Onwuemene OA, et al. Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the Writing committee of the American Society for apheresis: The Ninth Special Issue. J Clin Apher 2023; 38(2): 77–278.

Radovic M, Balint B, Jovicic A. The use of therapeutic plasma exchange for treatment of acute polyradiculoneuropathy. Transfus Sci 1995; 16: 167–71.

Balint B, Todorovic M, Ostojic G, Vucetic D. Plasma remov-al/exchange efficacy: Spectra-Optia versus Cobe-Spectra – A comparative preclinical study. J Clin Apher 2013; 28: 126.

Balint B, Radovic M, Malesevic M, Jovicic A, Stamatovic D, Ostojic G. The rationale for therapeutic apheresis in the treatment of hematologic and immune–mediated neurologic disorders. Blood Banking Transf Med 2003; 1(2): 73–80.

Balint B, Pavlovic M, Todorovic M. The use of apheresis in per-sonalized cell-mediated treatment of prostate cancer. In: Kocic G, Hadzi Djokic J, Simic T, editors. Prostate cancer: advance-ments in the pathogenesis, diagnosis and personalized therapy. Heidelberg: Springer-Nature; 2024. p. 263–93.

Tormey CA, Peddinghaus ME, Erickson M, King KE, Cushing MM, Bill J, et al. Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform. Transfusion 2010; 50(2): 471–7.

Henze T, Prange HW, Talartschik J, Rumpf KW. Complications of plasma exchange in patients with neurological diseases. Klin Wochenschr 1990; 68(23): 1183–8.

Moudgil KD, Venkatesha SH. The anti-inflammatory and im-munomodulatory activities of natural products to control au-toimmune inflammation. Int J Mol Sci 2022; 24(1): 95.

Foettinger F, Pilz G, Wipfler P, Harrer A, Kern JM, Trinka E, et al. Immunomodulatory aspects of therapeutic plasma ex-change in neurological disorders – a pilot study. Int J Mol Sci 2023; 24(7): 6552.

Hiew FL, Thit WM, Alexander M, Thirugnanam U, Siritho S, Tan K, et al. Consensus recommendation on the use of therapeutic plasma exchange for adult neurological diseases in Southeast Asia from the Southeast Asia therapeutic plasma exchange consortium. J Cent Nerv Syst Dis 2021; 13: 11795735211057314.

Liu JF, Wang WX, Xue J, Zhao CB, You HZ, Lu JH, et al. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and in-travenous immunoglobulin for the treatment of late-onset myasthenia gravis. Ther Apher Dial 2010; 14(2): 153–60.

Kumar R, Birinder SP, Gupta S, Singh G, Kaur A. Therapeutic plasma exchange in the treatment of myasthenia gravis. Indian J Crit Care Med 2015; 19(1): 9–13.

Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002; 2002(4): CD002275.

Mandawat A, Kaminski HJ, Cutter G, Katirji B, Alshekhlee A. Comparative analysis of therapeutic options used for myas-thenia gravis. Ann Neurol 2010; 68(6): 797–805.

Tombak A, Uçar MA, Akdeniz A, Yilmaz A, Kaleagası H, Sun-gur MA, et al. Therapeutic plasma exchange in patients with neurologic disorders: Review of 63 cases. Indian J Hematol Blood Transfus 2017; 33(1): 97–105.

Yeh JH, Chiu HC. Plasmapheresis in myasthenia gravis. A comparative study of daily versus alternately daily schedule. Acta Neurol Scand 1999; 99(3): 147–51.

Dau PC. Increased proliferation of blood mononuclear cells after plasmapheresis treatment of patients with demyelinating disease. J Neuroimmunol 1990; 30(1): 15–21.

Dau PC. Increased antibody production in peripheral blood mononuclear cells after plasma exchange therapy in multiple sclerosis. J Neuroimmunol 1995; 62(2): 197–200.

Stricker RB, Miller RG, Kiprov DD. Role of plasmapheresis in acute disseminated (postinfectious) encephalomyelitis. J Clin Apher 1992; 7(4): 173–9.

Yoshii F, Shinohara Y. Lymphocyte subset proportions in Guil-lain-Barré syndrome patients treated with plasmapheresis. Eur Neurol 2000; 44(3): 162–7.

Reeves HM, Winters JL. The mechanisms of action of plasma exchange. Br J Haematol 2014; 164(3): 342–51.

Balint B, Jovicić A, Apostolski S, Magdić B, Taseski J. Plasma ex-change in myasthenia gravis and multiple sclerosis. Vojnosanit Pregl 2000; 57(5): 11–5.

Balili K, Louhab N, Adarmouch L, Chraa M, Hachimi A, Bel-bachir A, et al. Guillain–Barre syndrome: small-volume plas-mapheresis versus intravenous immunoglobulin—3rd level hospital experience. Egypt J Neurol Psychiatry Neurosurg 2024; 60(1): 45.